Roche Holding AG (ROP) Fair Value & Analysis
Healthcare · CH · Market cap CHF 263B · ISIN CH1499059983
What is Roche Holding AG really worth?
A strong business, currently priced close to our fair value of CHF 357.30.
As of Sep 6, 2026, the fair value of Roche Holding AG is CHF 357.30 per share against a price of CHF 357.00, so the fair value sits 0% above the price. A model estimate blended from multiple valuation models, recalculated regularly.
Strengths
Risks
For context
Fair value as of: Sep 6, 2026
From 25 valuation models · updated today
Share price −2.1% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- A fairly wide model range (CHF 226.97 to CHF 514.13) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 6, 2026.
How to read this chart
60‑month range CHF 201.09 – CHF 375.60 · fair‑value band CHF 226.97 – CHF 514.13 · the CHF 357.00 price screens below the CHF 357.30 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 6, 2026.
Analysis
Roche Holding AG (ROP) currently trades at CHF 357.00, while our model-based Fair Value estimate is CHF 357.30, implying the stock looks roughly 0.1% fairly valued today. The Quality Score stands at 76/100 (high quality), in the Healthcare sector. Bull case: the Growth Earnings group reads highest at a median of CHF 323.38 per share, and 5 of the 25 models we run sit above the CHF 357.00 price. Bear case: the Economic Profit group reads lowest at CHF 149.68, and 20 of the 25 models stay below the price. Evidence for this calculation is high.
Over the trailing twelve months, Roche Holding AG generated revenue of CHF 63.4B at a net margin of 20.3%. Revenue declined 0.4% year over year. It earns a return on equity of 37.3%. Net debt stands at CHF 27.6B. Fundamentals as of Sep 6, 2026
Our scenario range runs from CHF 226.97 (bear case) to CHF 514.13 (bull case); at CHF 357.00, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 2% below its 52-week high and 51% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −11% fair-value upside, at 0%, ROP screens cheaper than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly CHF 4.25 per share, which is 1.2 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 25 models by family
Widest divergence: Growth Earnings (CHF 323.38) versus Asset-Based (CHF 32.87). Highest evidence: FCF DCF (80).
Notify me when ROP reaches fair value
Put ROP on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Sep 6, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 73 · Market factors (momentum, volatility) 77
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand.
Full company description
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. The company was founded in 1896 and is based in Basel, Switzerland.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Roche Holding AG reported revenue of CHF 61.5B in FY2025 versus CHF 62.8B in FY2021, a compound −0.5%/yr. Reported net income was CHF 12.9B in FY2025, compounding −1.9%/yr from FY2021.
of which total revenue +2.1 % · buybacks/dilution +0.8 %
Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).
Watch ROP: get an alert when its fair value changes →
Recent news
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.
- Could Roche and Lilly’s Blood Test Make Alzheimer’s Assessment More Accessible?
- Treeline Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate TLN-121 in Combination with CD20xCD3 T-Cell-Enga
- 2026 Complement Inhibitors Market Analysis Report (2nd Edition) Featuring Amgen, CSL Behring, Innovent Biologics, Novartis, Regeneron, Roche
- Roche Commits $75 Million in Blood-Cancer Deal Worth Up to $1.53 Billion
Peer Group
Drug Manufacturers - General · 75 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - General median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 30/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Sep 6, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,176 | $389.47 | −67% |
| Johnson & Johnson, JNJ | $275.23 | $169.04 | −39% |
| AbbVie Inc ABBV | $256.46 | $67.72 | −74% |
| Merck & Co MRK | €131.98 | €101.38 | −23% |
| Novartis AG NOVN | CHF 123.74 | CHF 114.90 | −7% |
| Novo Nordisk A/S NOVOB | kr 295.50 | kr 409.46 | +39% |
| Amgen Inc AMGN | $437.23 | $252.02 | −42% |
| Gilead Sciences, Inc GILD | $151.00 | $146.50 | −3% |
| Pfizer Inc PFE | $28.02 | $24.87 | −11% |
| Bristol-Myers Squibb Company BMY | $66.58 | $75.98 | +14% |
Compare Roche Holding AG with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Roche Holding AG (ROP) overvalued or undervalued?
What is the fair value of ROP?
What is the quality score of ROP?
What is the price target for Roche Holding AG (ROP)?
What is the Roche Holding AG stock forecast for 2026?
What is the revenue of Roche Holding AG (ROP)?
What is the net profit margin of ROP?
Does Roche Holding AG pay a dividend?
Watch Roche Holding AG in the live analysis
One click puts Roche Holding AG on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.